AIM: To clarify how body mass index (BMI) affects the risk of death from upper urinary tract urothelial carcinoma (UUTUC) we investigated the impact of BMI on UUTUC using a Japanese multicenter database.
PATIENTS AND METHODS: Between January 1995 and December 2010, 1,329 patients with upper urinary tract tumors were treated in 13 institutions in Japan. From this group, a cohort of 1,014 patients treated with radical nephroureterectomy was retrospectively reviewed. BMI was categorized into the following three groups: BMI < 22.5, BMI 22.5 to < 25 and BMI ≥25. The association between each group and cancer-specific survival (CSS) was analyzed using Cox proportional hazards regression models.
RESULTS: The median BMI was 22.4 kg/m2 (interquartile range, 20.5-24.8). Out of all patients, 213 (21%) died of UUTUC. Hazard ratios of the BMI ≥25 and the BMI < 22.5 group were 1.76 and 1.66, respectively.
CONCLUSION: Both higher and lower BMI affect the prognosis of UUTUC treated with radical nephroureterectomy.
Written by:
Ishioka J, Masuda H, Kijima T, Tatokoro M, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Koga F, Saito K, Fujii Y, Sakai Y, Arisawa C, Okuno T, Nagahama K, Kamata S, Yonese J, Kageyama Y, Noro A, Morimoto S, Tsujii T, Kitahara S, Gotoh S, Kihara K. Are you the author?
Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan; Department of Urology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Urology, National Cancer Center Hospital East, Chiba, Japan; Department of Urology, East Tokyo Metropolitan Hospital, Tokyo, Japan; Department of Urology, JA Toride Medical Center, Ibaraki, Japan; Department of Urology, Kounodai Hospital, National Center for Global Health and Medicine, Chiba, Japan; Department of Urology, Soka Municipal Hospital, Saitama, Japan; Department of Urology Saitama Cancer Center, Saitama, Japan; Department of Urology, Saitama Red Cross Hospital, Saitama, Japan; Department of Urology, Tsuchiura Kyodo General Hospital, Ibaraki, Japan; Department of Urology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan; Department of Urology, Tama-Nanbu Chiiki Hospital, Tokyo, Japan; Department of Urology, Hamamatsu Medical Center, Shizuoka, Japan.
Reference: Anticancer Res. 2014 Oct;34(10):5683-8.
PubMed Abstract
PMID: 25275074